Recent Progress in Development of Dopamine Receptor Subtype-Selective Agents: Potential Therapeutics for Neurological and Psychiatric Disorders

Multiple receptors for dopamine

Kebabian, J. W., & Calne, D. B. (1979) · Nature · doi:10.1038/277093a0 · Cited by 3,725

A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel

Sanguinetti, M. C., Jiang, C., Curran, M. E., & Keating, M. T. (1995) · Cell · doi:10.1016/0092-8674(95)90340-2 · Cited by 2,423

Brain dopamine receptors.

Seeman, P. (1980) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06839-5 · Cited by 1,892

Dopamine in drug abuse and addiction: results from imaging studies and treatment implications

Volkow, N. D., Fowler, J. S., Wang, G.-J., & Swanson, J. M. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001507 · Cited by 1,101

Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology

Shapiro, D. A., Renock, S., Arrington, E., Chiodo, L. A., Liu, L.-X., Sibley, D. R., Roth, B. L., & Mailman, R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300203 · Cited by 968

Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats

Ernst, A. M. (1967) · Psychopharmacologia · doi:10.1007/bf00403900 · Cited by 906

SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems.

Iorio, L. C., Barnett, A., Leitz, F. H., Houser, V. P., & Korduba, C. A. (1983) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21599-3 · Cited by 896

Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence

Arnt, J. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00112-7 · Cited by 715

Burger's Medicinal Chemistry and Drug Discovery

(1997) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(97)84367-x · Cited by 676

Review: D1 dopamine receptor—the search for a function: A critical evaluation of the D1/D2 dopamine receptor classification and its functional implications

Clark, D., & White, F. J. (1987) · Synapse · doi:10.1002/syn.890010408 · Cited by 660

The central effects of a novel dopamine agonist

Setler, P. E., Sarau, H. M., Zirkle, C. L., & Saunders, H. L. (1978) · European Journal of Pharmacology · doi:10.1016/0014-2999(78)90148-6 · Cited by 639

Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist

Fletcher, A., Forster, E. A., Bill, D. J., Brown, G., Cliffe, I. A., Hartley, J. E., Jones, D. E., McLenachan, A., Stanhope, K. J., Critchley, D. J. P., et al. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00118-0 · Cited by 525

Blockade of cocaine reinforcement in rats with the dopamine receptor blocker pimozide, but not with the noradrenergic blockers phentolamine or phenoxybenzamine.

de Wit, H., & Wise, R. A. (1977) · Canadian Journal of Psychology / Revue canadienne de psychologie · doi:10.1037/h0081662 · Cited by 491

5-HT1A receptor agonists: recent developments and controversial issues

De Vry, J. (1995) · Psychopharmacology · doi:10.1007/bf02245588 · Cited by 455

Whole-cell response of the pennate diatom Phaeodactylum tricornutum to iron starvation

Allen, A. E., LaRoche, J., Maheswari, U., Lommer, M., Schauer, N., Lopez, P. J., Finazzi, G., Fernie, A. R., & Bowler, C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711370105 · Cited by 445

Absence of opiate rewarding effects in mice lacking dopamine D2 receptors

Maldonado, R., Saiardi, A., Valverde, O., Samad, T. A., Roques, B. P., & Borrelli, E. (1997) · Nature · doi:10.1038/41567 · Cited by 434

Modeling of G-protein-coupled receptors: application to dopamine, adrenaline, serotonin, acetylcholine, and mammalian opsin receptors

Trumpp-Kallmeyer, S., Hoflack, J., Bruinvels, A., & Hibert, M. (1992) · Journal of Medicinal Chemistry · doi:10.1021/jm00097a002 · Cited by 417

Do we still believe in the dopamine hypothesis? New data bring new evidence

Abi-Dargham, A. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004110 · Cited by 361

Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.

Kehne, J. H., Baron, B. M., Carr, A. A., Chaney, S. F., Elands, J., Feldman, D. J., Frank, R. A., van Giersbergen, P. L., McCloskey, T. C., Johnson, M. P., et al. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12956-x · Cited by 358

Localization of D1 dopamine receptor mRNA in brain supports a role in cognitive, affective, and neuroendocrine aspects of dopaminergic neurotransmission.

Fremeau, R. T., Duncan, G. E., Fornaretto, M. G., Dearry, A., Gingrich, J. A., Breese, G. R., & Caron, M. G. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.9.3772 · Cited by 354

BindingDB Entry 4838: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.

BindingDB (2011) · PubMed · doi:10.7270/q2cr5rw8 · Cited by 333

Antagonism of dopamine D2 receptor/β-arrestin 2 interaction is a common property of clinically effective antipsychotics

Masri, B., Salahpour, A., Didriksen, M., Ghisi, V., Beaulieu, J.-M., Gainetdinov, R. R., & Caron, M. G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803522105 · Cited by 320

Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat

Grenhoff, J., Nisell, M., Ferr�, S., Aston-Jones, G., & Svensson, T. H. (1993) · Journal of Neural Transmission · doi:10.1007/bf01244934 · Cited by 292

Dopamine Synthesis, Uptake, Metabolism, and Receptors: Relevance to Gene Therapy of Parkinson's Disease

Elsworth, J. D., & Roth, R. H. (1997) · Experimental Neurology · doi:10.1006/exnr.1996.6379 · Cited by 285

The regulation of forebrain dopamine transmission: relevance to the pathophysiology and psychopathology of schizophrenia

Moore, H., West, A. R., & Grace, A. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00078-5 · Cited by 274

The role of dopamine in reward and pleasure behaviour – review of data from preclinical research

Bressan, R. A., & Crippa, J. A. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2005.00540.x · Cited by 254

3-[[4-(4-Chlorophenyl)piperazin-1-yl]methyl]-1 H-pyrrolo[2,3-b]pyridine: An Antagonist with High Affinity and Selectivity for the Human Dopamine D4 Receptor

Kulagowski, J. J., Broughton, H. B., Curtis, N. R., Mawer, I. M., Ridgill, M. P., Baker, R., Emms, F., Freedman, S. B., Marwood, R., Patel, S., et al. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9600712 · Cited by 252

Dopamine D3 receptor antagonists as therapeutic agents

Joyce, J. N., & Millan, M. J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03491-4 · Cited by 237

Radiosynthesis and Evaluation of [11C]-(+)-4-Propyl-3,4,4a,5,6,10b-hexahydro-2 H-naphtho[1,2-b][1,4]oxazin-9-ol as a Potential Radiotracer for in Vivo Imaging of the Dopamine D2 High-Affinity State with Positron Emission Tomography

Wilson, A. A., McCormick, P., Kapur, S., Willeit, M., Garcia, A., Hussey, D., Houle, S., Seeman, P., & Ginovart, N. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050155n · Cited by 226

Selective Optimization of Side Activities: Another Way for Drug Discovery

Wermuth, C. G. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030480f · Cited by 201

Aripiprazole has Functionally Selective Actions at Dopamine D2 Receptor-Mediated Signaling Pathways

Urban, J. D., Vargas, G. A., von Zastrow, M., & Mailman, R. B. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301071 · Cited by 197

Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons

Chiodo, L., & Bunney, B. (1985) · The Journal of Neuroscience · doi:10.1523/jneurosci.05-09-02539.1985 · Cited by 195

Interactive SAR Studies: Rational Discovery of Super-Potent and Highly Selective Dopamine D3 Receptor Antagonists and Partial Agonists

Bettinetti, L., Schlotter, K., Hübner, H., & Gmeiner, P. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025558r · Cited by 194

Dopamine D3 Receptor Partial Agonists and Antagonists as Potential Drug Abuse Therapeutic Agents

Newman, A. H., Grundt, P., & Nader, M. A. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040190e · Cited by 190

Prazosin modulates the firing pattern of dopamine neurons in rat ventral tegmental area

Grenhoff, J., & Svensson, T. H. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90351-h · Cited by 190

GRID/CPCA: A New Computational Tool To Design Selective Ligands

Kastenholz, M. A., Pastor, M., Cruciani, G., Haaksma, E. E. J., & Fox, T. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000934y · Cited by 185

The Antipsychotic Agent Sertindole is a High Affinity Antagonist of the Human Cardiac Potassium Channel HERG

Rampe, D., Murawsky, M. K., Grau, J., & Lewis, E. W. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37654-2 · Cited by 172

Conjugated Enynes as Nonaromatic Catechol Bioisosteres: Synthesis, Binding Experiments, and Computational Studies of Novel Dopamine Receptor Agonists Recognizing Preferentially the D3Subtype

Hübner, H., Haubmann, C., Utz, W., & Gmeiner, P. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm991098z · Cited by 170

Trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist

Brewster, W. K., Nichols, D. E., Riggs, R. M., Mottola, D. M., Lovenberg, T. W., Lewis, M. H., & Mailman, R. B. (1990) · Journal of Medicinal Chemistry · doi:10.1021/jm00168a034 · Cited by 168

In vivo vulnerability to competition by endogenous dopamine: Comparison of the D2 receptor agonist radiotracer (–)‐N‐[11C]propyl‐norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]‐raclopride

Narendran, R., Hwang, D., Slifstein, M., Talbot, P. S., Erritzøe, D., Huang, Y. H., Cooper, T. B., Martínez, D., Kegeles, L. S., Abi‐Dargham, A., et al. (2004) · Synapse · doi:10.1002/syn.20013 · Cited by 159

The alpha1-Adrenergic Antagonist Prazosin Ameliorates Combat Trauma Nightmares in Veterans With Posttraumatic Stress Disorder

Raskind, M. A., Dobie, D. J., Kanter, E. D., Petrie, E. C., Thompson, C. E., & Peskind, E. R. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0208 · Cited by 154

Partial dopamine agonists in the treatment of psychosis

Tamminga, C. A. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200033 · Cited by 150

Cocaine Enhances NMDA Receptor-Mediated Currents in Ventral Tegmental Area Cells via Dopamine D5Receptor-Dependent Redistribution of NMDA Receptors

Schilström, B., Yaka, R., Argilli, E., Suvarna, N. U., Schumann, J., Chen, B. T., Carman, M., Singh, V., Mailliard, W. S., Dorit Ron, A., et al. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.5179-05.2006 · Cited by 150

2-Substituted Tryptamines: Agents with Selectivity for 5-HT6Serotonin Receptors

Glennon, R. A., Lee, M., Rangisetty, J. B., Dukat, M., Roth, B. L., Savage, J. E., McBride, A., Rauser, L., Hufeisen, S., & Lee, D. K. H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990550b · Cited by 149

Dopamine D1receptor ligands: Where are we now and where are we going

Zhang, J., Xiong, B., Zhen, X., & Zhang, A. (2008) · Medicinal Research Reviews · doi:10.1002/med.20130 · Cited by 146

SKF83959 selectively regulates phosphatidylinositol‐linked D1 dopamine receptors in rat brain

Jin, L., Goswami, S. K., Cai, G., Zhen, X., & Friedman, E. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01698.x · Cited by 140

Dopamine receptor subtype imbalance in schizophrenia

Hess, E. J., Bracha, H. S., Kleinman, J. E., & Creese, I. (1987) · Life Sciences · doi:10.1016/0024-3205(87)90381-x · Cited by 139

Do Central Antiadrenergic Actions Contribute to the Atypical Properties of Clozapine?

Baldessarini, R. J., Huston-Lyons, D., Campbell, A., Marsh, E. R., & Cohen, B. M. (1992) · The British Journal of Psychiatry · doi:10.1192/s0007125000296852 · Cited by 134

Schizophrenia and L-745, 870, a novel dopamine D4 receptor antagonist

Bristow, L. J., Kramer, M. S., Kulagowski, J. J., Patel, S. S., RAGAN, C. I., & Seabrook, G. R. (1997) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)01066-3 · Cited by 132

Design and Synthesis of trans-N-[4-[2-(6-Cyano-1,2,3,4-tetrahydroisoquinolin-2- yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A Potent and Selective Dopamine D3 Receptor Antagonist with High Oral Bioavailability and CNS Penetration in the Rat

Stemp, G., Ashmeade, T. E., Branch, C. L., Hadley, M. S., Hunter, A. J., Johnson, C. N., Nash, D. J., Thewlis, K. M., Vong, A. K. K., Austin, N. E., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000090i · Cited by 131

Molecular Modeling of the Three-Dimensional Structure of Dopamine 3 (D3) Subtype Receptor: Discovery of Novel and Potent D3Ligands through a Hybrid Pharmacophore- and Structure-Based Database Searching Approach

Varady, J., Wu, X., Fang, X., Ji, M., Hu, Z., Levant, B., & Wang, S. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030085p · Cited by 131

Current and Novel Approaches to the Drug Treatment of Schizophrenia

Rowley, M., Bristow, L. J., & Hutson, P. H. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0002432 · Cited by 128

Novel Heterocyclic Trans Olefin Analogues of N-{4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as Selective Probes with High Affinity for the Dopamine D3 Receptor

Grundt, P., Carlson, E. E., Cao, J., Bennett, C. J., McElveen, E., Taylor, M., Luedtke, R. R., & Newman, A. H. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049465g · Cited by 127

New Antipsychotics and Schizophrenia: A Review on Efficacy and Side Effects

Serretti, A., Ronchi, D. D., Lorenzi, C., & Berardi, D. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043456043 · Cited by 121

Activation of dopamine D 4 receptors by ABT-724 induces penile erection in rats

Brioni, J. D., Moreland, R. B., Cowart, M., Hsieh, G. C., Stewart, A. O., Hedlund, P., Donnelly‐Roberts, D. L., Nakane, M., Lynch, J. J., Kolasa, T., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308292101 · Cited by 116

N-(ω-(4-(2-Methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as Dopamine D2 and D3 Receptor Ligands

Hackling, A. E., Ghosh, R., Perachon, S., Mann, A., Höltje, H., Wermuth, C. G., Schwartz, J.-C., Sippl, W., Sokoloff, P., & Stark, H. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030836n · Cited by 106

Neuroprotective effect of 5-HT1A receptor agonist, Bay×3702, demonstrated in vitro and in vivo

Semkova, I., Wolz, P., & Krieglstein, J. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00634-7 · Cited by 103

Phencyclidine-Induced Deficits in Prepulse Inhibition of Startle are Blocked by Prazosin, an Alpha-1 Noradrenergic Antagonist

Bakshi, V. P., & Geyer, M. A. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37049-1 · Cited by 99

Dopamine D1/D5 Receptor Antagonists with Improved Pharmacokinetics: Design, Synthesis, and Biological Evaluation of Phenol Bioisosteric Analogues of Benzazepine D1/D5 Antagonists

Wu, W., Burnett, D. A., Spring, R., Greenlee, W. J., Smith, M., Favreau, L. V., Fawzi, A. B., Zhang, H., & Lachowicz, J. E. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm030614p · Cited by 93

Receptor affinities of dopamine D1 receptor-selective novel phenylbenzazepines

Neumeyer, J. L. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)02008-9 · Cited by 93

Rationally Based Efficacy Tuning of Selective Dopamine D4 Receptor Ligands Leading to the Complete Antagonist 2-[4-(4-Chlorophenyl)piperazin-1- ylmethyl]pyrazolo[1,5- a ]pyridine (FAUC 213)

Löber, S., Hübner, H., Utz, W., & Gmeiner, P. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm015522j · Cited by 93

Conformationally-flexible benzamide analogues as dopamine D3 and σ2 receptor ligands

Mach, R. H., Huang, Y., Freeman, R. A., Wu, L. G., Vangveravong, S., & Luedtke, R. R. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.09.083 · Cited by 93

(−)-N-[11C]propyl-norapomorphine: a positron-labeled dopamine agonist for PET imaging of D2 receptors

Hwang, D., Kegeles, L., & Laruelle, M. (2000) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(00)00144-x · Cited by 93

SKF83959 exhibits biochemical agonism by stimulating [35S]GTPγS binding and phosphoinositide hydrolysis in rat and monkey brain

Panchalingam, S., & Undie, A. S. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00011-9 · Cited by 92

Quetiapine fumarate (Seroquel(R)): A new atypical antipsychotic

Goldstein, J. M. (1999) · Drugs of today · doi:10.1358/dot.1999.35.3.533849 · Cited by 91

A preliminary PET evaluation of the new dopamine D2 receptor agonist [11C]MNPA in cynomolgus monkey

Finnema, S. J., Seneca, N. M., Farde, L., Shchukin, E., Sóvágó, J., Gulyás, B. Z., Wikström, H., Innis, R. B., Neumeyer, J. L., & Halldin, C. (2005) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2005.01.007 · Cited by 91

Central α1-adrenoceptors

Sirviö, J., & MacDonald, E. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00017-0 · Cited by 90

Heterocyclic Analogues ofN-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with Functionalized Linking Chains as Novel Dopamine D3 Receptor Ligands: Potential Substance Abuse Therapeutic Agents

Grundt, P., Prevatt, K. M., Cao, J., Taylor, M., Floresca, C. Z., Choi, J., Jenkins, B. G., Luedtke, R. R., & Newman, A. H. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0704200 · Cited by 89

The dopamine hypothesis of schizophrenia: current status, future prospects

Willner, P. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199711000-00002 · Cited by 87

A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia

Mu, Q., Johnson, K. A., Morgan, P. S., Grenesko, E. L., Molnar, C., Anderson, B. S., Nahas, Z. H., Kozel, F. A., Köse, S., Knable, M. B., et al. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.03.033 · Cited by 87

A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia

George, M. S., Molnar, C., Grenesko, E. L., Anderson, B. S., Mu, Q., Johnson, K. A., Nahas, Z. H., Knable, M. B., FERNANDES, P. B., Juncos, J. L., et al. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.03.011 · Cited by 85

The 5-HT1A receptor and its ligands: structure and function

Olivier, B., Soudijn, W., & van Wijngaarden, I. (1999) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8730-4_3 · Cited by 83

Evaluation of Dopamine D-2 Receptor Occupancy by Clozapine, Risperidone, and Haloperidol In Vivo in the Rodent and Nonhuman Primate Brain Using 18F-Fallypride

Mukherjee, J., Christian, B. T., Narayanan, T. K., Shi, B., & Mantil, J. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00251-2 · Cited by 81

Isoquinoline Alkaloids Isolated from Corydalis yanhusuo and Their Binding Affinities at the Dopamine D1 Receptor

Ma, Z.-Z., Xu, W., Jensen, N., Roth, B. L., Liu‐Chen, L., & Lee, D. Y. W. (2008) · Molecules · doi:10.3390/molecules13092303 · Cited by 80

Synthesis and Biological Evaluation of New Quinazoline and Cinnoline Derivatives as Potential Atypical Antipsychotics

Alvarado, M., Barceló, M., Carro, L., Masaguer, C. F., & Raviña, E. (2006) · Chemistry & Biodiversity · doi:10.1002/cbdv.200690001 · Cited by 78

Synthesis and binding affinity of new pyrazole and isoxazole derivatives as potential atypical antipsychotics

Barceló, M., Raviña, E., Masaguer, C. F., Domínguez, E., Areias, F. M., Brea, J. M., & Loza, M. I. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.06.045 · Cited by 78

Dopamine D3 Receptor Ligands with Antagonist Properties

Hackling, A. E., & Stark, H. (2002) · ChemBioChem · doi:10.1002/1439-7633(20021004)3:10<946::aid-cbic946>3.0.co;2-5 · Cited by 78

Positron Emission Tomography ofin-vivoBinding Characteristics of Atypical Antipsychotic Drugs: Review of D2and 5-HT2Receptor Occupancy Studies and Clinical Response

Nyberg, S., Nakashima, Y., Nordström, A., Halldin, C., & Farde, L. (1996) · The British Journal of Psychiatry · doi:10.1192/s0007125000298309 · Cited by 77

Pharmacological analysis of dopamine stimulation of [35S]‐GTPγS binding via human D2short and D2long dopamine receptors expressed in recombinant cells

Gardner, B., Hall, D. A., & Strange, P. G. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb15572.x · Cited by 76

Discovery of New Tetracyclic Tetrahydrofuran Derivatives as Potential Broad-Spectrum Psychotropic Agents

Fernández, J., Alonso, J. M., Andrés, J. I., Cid, J. M., Díaz, A., Iturrino, L., Gil, P., Megens, A. A. H. P., Sipido, V. K., & Trabanco, A. A. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049632c · Cited by 74

Design and Synthesis oftrans-3-(2-(4-((3-(3-(5-Methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro- 1H-3-benzazepine (SB-414796): A Potent and Selective Dopamine D3Receptor Antagonist

Macdonald, G. J., Branch, C. L., Hadley, M. S., Johnson, C. N., Nash, D. J., Smith, A. B., Stemp, G., Thewlis, K. M., Vong, A. K. K., Austin, N. E., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030817d · Cited by 74

Compounds selective for dopamine receptor subtypes

Kebabian, J. W., Tarazi, F. I., Kula, N. S., & Baldessarini, R. J. (1997) · Drug Discovery Today · doi:10.1016/s1359-6446(97)01075-1 · Cited by 72

Specific Binding of [ 11 C]Raclopride and N -[ 3 H]Propyl-Norapomorphine to Dopamine Receptors in Living Mouse Striatum: Occupancy by Endogenous Dopamine and Guanosine Triphosphate–Free G Protein

Cumming, P., Wong, D. F., Gillings, N., Hilton, J., Scheffel, U., & Gjedde, A. (2002) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200205000-00011 · Cited by 71

Design, synthesis and pharmacological profile of novel dopamine D2 receptor ligands

Menegatti, R., Cunha, A. C., Ferreira, V. F., Pereira, E. F. R., Elnabawi, A., Eldefrawi, A. T., Albuquerque, E. X., Neves, G. A., Rates, S. M. K., Fraga, C. A. M., et al. (2003) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(03)00487-5 · Cited by 71

Advances in Atypical Antipsychotics for the Treatment of Schizophrenia: New Formulations and New Agents

Kelleher, J. P., Centorrino, F., Albert, M. J., & Baldessarini, R. J. (2002) · CNS Drugs · doi:10.2165/00023210-200216040-00004 · Cited by 70

Disruption in prepulse inhibition after alpha-1 adrenoceptor stimulation in rats

Carasso, B. S., Bakshi, V. P., & Geyer, M. A. (1998) · Neuropharmacology · doi:10.1016/s0028-3908(98)00051-3 · Cited by 68

Randomized Controlled Trials of the D1/D5 Antagonist Ecopipam for Weight Loss in Obese Subjects

Astrup, A. V., Greenway, F. L., Ling, W. W., Pedicone, L. D., Lachowicz, J. E., Strader, C. D., Kwan, R., & Ecopipam Obesity Study Group (2007) · Obesity · doi:10.1038/oby.2007.205 · Cited by 67

Dopamine D5 Receptor Agonist High Affinity and Constitutive Activity Profile Conferred by Carboxyl-terminal Tail Sequence

Demchyshyn, L. L., McConkey, F., & Niznik, H. B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000157200 · Cited by 66

Synthesis and antitubercular activity of phenothiazines with reduced binding to dopamine and serotonin receptors

Madrid, P. B., Polgar, W. E., Toll, L., & Tanga, M. J. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.03.064 · Cited by 66

Selectively Bred Lines of Rats Differ in Social Interaction and Hippocampal 5-HT1A Receptor Function: A Link Between Anxiety and Depression?

Gonzalez, L. E., File, S. E., & Overstreet, D. H. (1998) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(97)00525-x · Cited by 66

Synthesis and Structure−Activity Relationships of a New Model of Arylpiperazines. 2. Three-Dimensional Quantitative Structure−Activity Relationships of Hydantoin−Phenylpiperazine Derivatives with Affinity for 5-HT1A and α1 Receptors. A Comparison of CoMFA Models

López-Rodríguez, M. L., Rosado, M. L., Benhamú, B., MORCILLO, M. J., Fernández, E., & Schaper, K. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960744g · Cited by 64

N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl, butenyl and butynyl}arylcarboxamides as novel dopamine D3 receptor antagonists

Newman, A. H., Cao, J., Bennett, C. J., Robarge, M. J., Freeman, R. A., & Luedtke, R. R. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00389-5 · Cited by 62

The antipsychotic potential of l-stepholidine—a naturally occurring dopamine receptor D1 agonist and D2 antagonist

Natesan, S., Reckless, G. E., Barlow, K. B. L., Odontiadis, J., Nóbrega, J. N., Baker, G. B., George, S. R., Mamo, D. C., & Kapur, S. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1172-1 · Cited by 62

Discovery of 2-(4-Pyridin-2-ylpiperazin-1-ylmethyl)-1 H -benzimidazole (ABT-724), a Dopaminergic Agent with a Novel Mode of Action for the Potential Treatment of Erectile Dysfunction

Cowart, M., Latshaw, S. P., Bhatia, P. A., Daanen, J. F., Rohde, J. J., Nelson, S. L., Patel, M. A., Kolasa, T., Nakane, M., Uchic, M. E., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030505a · Cited by 61

2-[(4-Phenylpiperazin-1-yl)methyl]imidazo(di)azines as Selective D4-Ligands. Induction of Penile Erection by 2-[4-(2-Methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-a]pyridine (PIP3EA), a Potent and Selective D4Partial Agonist

Enguehard‐Gueiffier, C., Hübner, H., Hakmaoui, A. E., Allouchi, H., Gmeiner, P., Argiolas, A., Melis, M. R., & Gueiffier, A. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060166w · Cited by 61

Synthesis, Structure−Activity Relationships, and Biological Properties of 1-Heteroaryl-4-[ω-(1H-indol-3-yl)alkyl]piperazines, Novel Potential Antipsychotics Combining Potent Dopamine D2 Receptor Antagonism with Potent Serotonin Reuptake Inhibition

Smid, P., Coolen, H. K. A. C., Keizer, H. G., van Hes, R., de Moes, J., den Hartog, A. P., Stork, B., Plekkenpol, R. H., Niemann, L. C., Stroomer, C. N. J., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050148z · Cited by 60

Parallel Synthesis and Biological Screening of Dopamine Receptor Ligands Taking Advantage of a Click Chemistry Based BAL Linker

Bettinetti, L., Löber, S., Hübner, H., & Gmeiner, P. (2005) · Journal of Combinatorial Chemistry · doi:10.1021/cc049860s · Cited by 60

SLV313 (1-(2,3-Dihydro-Benzo[1,4]Dioxin-5-yl)-4- [5-(4-Fluoro-Phenyl)-Pyridin-3-ylmethyl]-Piperazine Monohydrochloride): A Novel Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist Potential Antipsychotic Drug

McCreary, A. C., Glennon, J. C., Ashby, C. R., Meltzer, H. Y., Li, Z., Reinders, J. H., Hesselink, M. B., Long, S., Herremans, A. H. J., van Stuivenberg, H. H., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301098 · Cited by 59

Neuroprotective effects of atypical D1 receptor agonist SKF83959 are mediated via D1 receptor‐dependent inhibition of glycogen synthase kinase‐3β and a receptor‐independent anti‐oxidative action

Yu, Y., Wang, J., Sun, P., Guo, Y., Zhang, Z., Jin, G.-Z., & Zhen, X. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05062.x · Cited by 59

Novel Ergopeptides as Dual Ligands for Adenosine and Dopamine Receptors

Vendrell, M., Angulo-Pueyo, E., Casadó, V., Lluís, C., Franco, R., Alberício, F., & Royo, M. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm060947x · Cited by 59

New 5-HT1A receptor agonists possessing 1,4-Benzoxazepine scaffold exhibit highly potent anti-ischemic effects

Kamei, K., Maeda, N., Ogino, R., Koyama, M., Nakajima, M., Tatsuoka, T., Ohno, T., & Inoue, T. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00008-7 · Cited by 57

Synthesis and Structure−Activity Relationships of a New Model of Arylpiperazines. 5. Study of the Physicochemical Influence of the Pharmacophore on 5-HT1A/α1-Adrenergic Receptor Affinity: Synthesis of a New Derivative with Mixed 5-HT1A/D2 Antagonist Properties

López-Rodríguez, M. L., MORCILLO, M. J., Fernández, E., Porras, E., Orensanz, L. M., Beneytez, M. E., Manzanares, J., & Fuentes, J. A. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000929u · Cited by 55

Cyanoindole Derivatives as Highly Selective Dopamine D4Receptor Partial Agonists: Solid-Phase Synthesis, Binding Assays, and Functional Experiments

Hübner, H., Kraxner, J., & Gmeiner, P. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm0009989 · Cited by 54

8,9-Dihydroxy-2,3,7,11b-tetrahydro-1 H -naph[1,2,3- de ]isoquinoline: A Potent Full Dopamine D 1 Agonist Containing a Rigid β-Phenyldopamine Pharmacophore

Ghosh, D., Snyder, S. E., Watts, V. J., Mailman, R. B., & Nichols, D. E. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm950707+ · Cited by 52

Studies towards the identification of a new generation of atypical antipsychotic agents

Garzya, V., Forbes, I. T., Gribble, A. D., Hadley, M. S., Lightfoot, A. P., Payne, A. H., Smith, A. B., Douglas, S. E., Cooper, D. G., Stansfield, I. G., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.10.036 · Cited by 52

Fused Azaindole Derivatives: Molecular Design, Synthesis and In Vitro Pharmacology Leading to the Preferential Dopamine D3 Receptor Agonist FAUC 725

Löber, S., Hübner, H., & Gmeiner, P. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00390-6 · Cited by 52

trans-2,3-Dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: Synthesis, Resolution, and Preliminary Pharmacological Characterization of a New Dopamine D1Receptor Full Agonist

Cueva, J. P., Giorgioni, G., Grubbs, R. A., Chemel, B. R., Watts, V. J., & Nichols, D. E. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0604979 · Cited by 51

Enhancement of antipsychotic-like effects by combined treatment with the α 1 -adrenoceptor antagonist prazosin and the dopamine D 2 receptor antagonist raclopride in rats

Wadenberg, M.-L., Hertel, P., Fernholm, R., Blakeman, K. H., Ahlenius, S., & Svensson, T. H. (2000) · Journal of Neural Transmission · doi:10.1007/s007020070036 · Cited by 51

Structure−Selectivity Investigations of D2-Like Receptor Ligands by CoMFA and CoMSIA Guiding the Discovery of D3Selective PET Radioligands

Salama, I., Hocke, C., Utz, W., Prante, O., Boeckler, F. M., Hübner, H., Kuwert, T., & Gmeiner, P. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0611152 · Cited by 49

Dihydrexidine — The First Full Dopamine D1Receptor Agonist

Salmi, P., Isacson, R., & Kull, B. (2004) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2004.tb00024.x · Cited by 48

The 5-HT1A receptor agonist Bay×3702 inhibits apoptosis induced by serum deprivation in cultured neurons

Ahlemeyer, B., Glaser, A., Schaper, C., Semkova, I., & Krieglstein, J. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00136-3 · Cited by 46

Synthesis and characterization of selective dopamine D2 receptor antagonists

Vangveravong, S., McElveen, E., Taylor, M., Xu, J., Tu, Z., Luedtke, R. R., & Mach, R. H. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.09.008 · Cited by 45

Discovery of 3-Methyl- N -(1-oxy-3‘,4‘,5‘,6‘-tetrahydro-2‘ H -[2,4‘-bipyridine]-1‘-ylmethyl)benzamide (ABT-670), an Orally Bioavailable Dopamine D 4 Agonist for the Treatment of Erectile Dysfunction

Patel, M. A., Kolasa, T., Mortell, K. H., Matulenko, M. A., Hakeem, A. A., Rohde, J. J., Nelson, S. L., Cowart, M., Nakane, M., Miller, L. N., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060662k · Cited by 45

Dopamine D5 receptor modulates male and female sexual behavior in mice

Kudwa, A. E., Domínguez-Salazar, E., Cabrera, D. M., Sibley, D. R., & Rissman, E. F. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2150-5 · Cited by 45

Comparative Molecular Field Analysis of Dopamine D4 Receptor Antagonists Including 3-[4-(4-Chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine (FAUC 113), 3-[4-(4-Chlorophenyl)piperazin-1-ylmethyl]-1H-pyrrolo[2,3-b]pyridine (L-745,870), and Clozapine

Lanig, H., Utz, W., & Gmeiner, P. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm001055e · Cited by 44

Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease

Zhang, H., Ma, L., Wang, F., Chen, J., & Zhen, X. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.04.004 · Cited by 44

A 3D QSAR Study on a Set of Dopamine D 4 Receptor Antagonists

Boström, J., Böhm, M., Gundertofte, K., & Klebe, G. (2003) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci034004+ · Cited by 44

Novel D3 Selective Dopaminergics Incorporating Enyne Units as Nonaromatic Catechol Bioisosteres: Synthesis, Bioactivity, and Mutagenesis Studies

Dörfler, M., Tschammer, N., Hamperl, K., Hübner, H., & Gmeiner, P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800895v · Cited by 43

Combined antagonism of adrenoceptors and dopamine and 5-HT receptors underlies the atypical profile of clozapine

Prinssen, E. P. M., Ellenbroek, B. A., & Cools, A. R. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90041-8 · Cited by 43

Design, Synthesis, and Evaluation of Metabolism-Based Analogues of Haloperidol Incapable of Forming MPP+-like Species

Lyles-Eggleston, M., Altundaş, R., Xia, J., Sikazwe, D., Fan, P., Yang, Q., Li', S., Zhang, W., Zhu, X., Schmidt, A. W., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0301033 · Cited by 43

Synthesis and biological investigations of dopaminergic partial agonists preferentially recognizing the D4 receptor subtype

Löber, S., Hübner, H., & Gmeiner, P. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.02.075 · Cited by 43

Synthesis, Radiofluorination, and In Vitro Evaluation of Pyrazolo[1,5-a]pyridine-Based Dopamine D4Receptor Ligands: Discovery of an Inverse Agonist Radioligand for PET

Prante, O., Tietze, R., Hocke, C., Löber, S., Hübner, H., Kuwert, T., & Gmeiner, P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701375u · Cited by 41

Pharmacophore-Guided Drug Discovery Investigations Leading to Bioactive 5-Aminotetrahydropyrazolopyridines. Implications for the Binding Mode of Heterocyclic Dopamine D3 Receptor Agonists

Elsner, J., Boeckler, F. M., Heinemann, F. W., Hübner, H., & Gmeiner, P. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0503805 · Cited by 41

Pyrrolo[1,3]benzothiazepine-Based Atypical Antipsychotic Agents. Synthesis, Structure−Activity Relationship, Molecular Modeling, and Biological Studies

Campiani, G., Butini, S., Gemma, S., Nacci, V., Fattorusso, C., Catalanotti, B., Giorgi, G., Cagnotto, A., Goegan, M., Mennini, T., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010982y · Cited by 41

Analogues of the dopamine D2 receptor antagonist L741,626: Binding, function, and SAR

Grundt, P., Husband, S. L. J., Luedtke, R. R., Taylor, M., & Newman, A. H. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.10.076 · Cited by 40

A novel series of hybrid compounds derived by combining 2-aminotetralin and piperazine fragments: binding activity at D2 and D3 receptors

Dutta, A. K., Fei, X., & Reith, M. E. A. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00820-4 · Cited by 40

F15063, a potential antipsychotic with D2/D3antagonist, 5‐HT1Aagonist and D4partial agonist properties: (I)in vitroreceptor affinity and efficacy profile

Newman‐Tancredi, A., Assié, M. B., Martel, J.-C., Cosi, C., Slot, L. A. B., Palmier, C., Rauly‐Lestienne, I., Colpaert, F. C., Vacher, B., & Cussac, D. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707158 · Cited by 39

In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): A novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist

Glennon, J. C., van Scharrenburg, G., Ronken, E., Hesselink, M. B., Reinders, J., van der Neut, M., Long, S., Feenstra, R. W., & McCreary, A. C. (2006) · Synapse · doi:10.1002/syn.20330 · Cited by 39

Adrenoreceptors and the pharmacology of affective illness: A unifying theory

Lipinski, J. F., Cohen, B. M., Zubenko, G. S., & WATERNAUX, C. M. (1987) · Life Sciences · doi:10.1016/0024-3205(87)90284-0 · Cited by 39

Prazosin, a specific alpha1-noradrenergic receptor antagonist, has no effect on symptoms but increases autonomic arousal in schizophrenic patients

Hommer, D. W., Zahn, T. P., Pickar, D., & van Kammen, D. P. (1984) · Psychiatry Research · doi:10.1016/0165-1781(84)90068-4 · Cited by 38

A dopamine receptor antagonist L-745,870 suppresses microglia activation in spinal cord and mitigates the progression in ALS model mice

Tanaka, K., Okada, Y., Kanno, T., Otomo, A., Yanagisawa, Y., Showguchi-Miyata, J., Suga, E., Kohiki, E., Onoe, K., Osuga, H., et al. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.02.004 · Cited by 38

New N-n-Propyl-Substituted 3-Aryl- and 3-Cyclohexylpiperidines as Partial Agonists at the D4 Dopamine Receptor

Macchia, M., Cervetto, L., Demontis, G. C., Longoni, B., Minutolo, F., Orlandini, E., Ortore, G., Papi, C., Sbrana, A., & Macchia, B. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm021019a · Cited by 38

Towards a New Generation of Potential Antipsychotic Agents Combining D2and 5-HT1AReceptor Activities

Cuisiat, S. V., Bourdiol, N., Lacharme, V., Newman‐Tancredi, A., Colpaert, F. C., & Vacher, B. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061180b · Cited by 37

Structure–affinity relationships of halogenated predicentrine and glaucine derivatives at D1 and D2 dopaminergic receptors: halogenation and D1 receptor selectivity

Asencio, M., Hurtado‐Guzmán, C., López, J. J., Cassels, B. K., Protais, P., & Chagraoui, A. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.03.022 · Cited by 37

Synthesis and radioiodination of selective ligands for the dopamine D3 receptor subtype

Hocke, C., Prante, O., Löber, S., Hübner, H., Gmeiner, P., & Kuwert, T. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.05.052 · Cited by 36

Synthesis and functional activity of (2-aryl-1-piperazinyl)-N-(3-methylphenyl)acetamides: selective dopamine D4 receptor agonists

Matulenko, M. A., Hakeem, A. A., Kolasa, T., Nakane, M., Terranova, M. A., Uchic, M. E., Miller, L. N., Chang, R., Donnelly‐Roberts, D. L., Namovic, M. T., et al. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.04.035 · Cited by 36

Drugs in development for Parkinson's disease: an update.

Johnston, T. H., & Brotchie, J. M. (2006) · PubMed · Cited by 36

Synthesis, Binding Affinity, and Molecular Docking Analysis of New Benzofuranone Derivatives as Potential Antipsychotics

Aranda, R., Villalba, K., Raviña, E., Masaguer, C. F., Brea, J. M., Areias, F. M., Domínguez, E., Selent, J., López, L., Sanz, F., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800602w · Cited by 35

Genetics of alcohol and other abused drugs

Crabbe, J. C., & Phillips, T. J. (1998) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00066-0 · Cited by 33

Atypical and typical antipsychotic drug interactions with the dopamine D2 receptor

Hjerde, E., Dahl, S. G., & Sylte, I. (2005) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2004.10.010 · Cited by 33

11C-Fallypride: radiosynthesis and preliminary evaluation of a novel dopamine D2/D3 receptor PET radiotracer in non-human primate brain

Mukherjee, J., Shi, B., Christian, B. T., et al. (2003) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2003.10.020 · Cited by 33

Improved asymmetric synthesis of dopamine D1 full agonist, dihydrexidine, employing chiral ligand-controlled asymmetric conjugate addition of aryllithium to a nitroalkene

Yamashita, M., Yamada, K., & Tomioka, K. (2004) · Tetrahedron · doi:10.1016/j.tet.2004.03.039 · Cited by 32

Kinetics of the uptake and distribution of the dopamine D2,3 agonist (R)-N-[1-11C]n-propylnorapomorphine in brain of healthy and MPTP-treated Göttingen miniature pigs

Cumming, P. D., Gillings, N., Jensen, S. B., Bjarkam, C. R., & GJEDDE, A. H. (2003) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(02)00448-1 · Cited by 31

Synthesis and evaluation of 18F-labeled dopamine D3 receptor ligands as potential PET imaging agents

Hocke, C., Prante, O., Löber, S., Hübner, H., Gmeiner, P., & Kuwert, T. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.07.037 · Cited by 31

Di- and trisubstituted pyrazolo[1,5-a]pyridine derivatives: synthesis, dopamine receptor binding and ligand efficacy

Löber, S., Tarek Aboul-fadl, A., Hübner, H., & Gmeiner, P. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00814-9 · Cited by 31

2,4-Disubstituted pyrroles: synthesis, traceless linking and pharmacological investigations leading to the dopamine D4 receptor partial agonist FAUC 356

Bergauer, M., Hübner, H., & Gmeiner, P. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00316-5 · Cited by 31

Benzamide bioisosteres incorporating dihydroheteroazole substructures: EPC synthesis and SAR leading to a selective dopamine D4 receptor partial agonist (FAUC 179)

Einsiedel, J., Hübner, H., & Gmeiner, P. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00484-x · Cited by 30

Strategy for Modulation of Central Dopamine Transmission Based on the Partial Agonist Concept in Schizophrenia Therapy

Inoue, A., & Nakata, Y. (2001) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.86.376 · Cited by 30

Synthesis and biological evaluation of new 4-arylpiperidines and 4-aryl-4-piperidinols: dual Na+ and Ca2+ channel blockers with reduced affinity for dopamine D2 receptors

Annoura, H., Nakanishi, K., Uesugi, M., Fukunaga, A., Imajo, S., Miyajima, A., Tamura‐Horikawa, Y., & Tamura, S. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(01)00288-7 · Cited by 29

Quantitative analysis of (-)-N-(11)C-propyl-norapomorphine in vivo binding in nonhuman primates.

Hwang, D. R., Narendran, R., Huang, Y. H., Slifstein, M., Talbot, P. S., Sudo, Y., van Berckel, B. N. M., Kegeles, L. S., Martinez, D., & Laruelle, M. A. (2004) · PubMed · Cited by 28

Fancy bioisosteres: synthesis and dopaminergic properties of the endiyne FAUC 88 as a novel non-aromatic D3 agonist

Lenz, C., Haubmann, C., Hübner, H., Boeckler, F. M., & Gmeiner, P. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.09.044 · Cited by 28

D5 Dopamine Receptor Knockout Mice and Hypertension

Yang, Z., Sibley, D. R., & José, P. A. (2004) · Journal of Receptors and Signal Transduction · doi:10.1081/lrst-200029971 · Cited by 28

Clozapine derived 2,3-dihydro-1H-1,4- and 1,5-benzodiazepines with D4 receptor selectivity: synthesis and biological testing

Hussenether, T., Hübner, H., Gmeiner, P., & Troschütz, R. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.03.023 · Cited by 27

Structure−Activity Relationships for a Novel Series of Dopamine D2-like Receptor Ligands Based on N-Substituted 3-Aryl-8-azabicyclo[3.2.1]octan-3-ol

Paul, N. M., Taylor, M., Kumar, R., Deschamps, J. R., Luedtke, R. R., & Newman, A. H. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800532x · Cited by 27

SLV310, a novel, potential antipsychotic, combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition

van Hes, R., Smid, P., Stroomer, C. N. J., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00996-4 · Cited by 27

Hybrid approach for the design of highly affine and selective dopamine D3 receptor ligands using privileged scaffolds of biogenic amine GPCR ligands

Sasse, B. C., Mach, U. R., Leppaenen, J., Calmels, T., & Stark, H. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.08.034 · Cited by 26

Dopamine Receptors and Clinical Medicine

Baldessarini, R. J. (1997) · Humana Press eBooks · doi:10.1007/978-1-4757-2635-0_15 · Cited by 25

Discovery of a dopamine D4 selective PET ligand candidate taking advantage of a click chemistry based REM linker

Tietze, R., Löber, S., Hübner, H., Gmeiner, P., Kuwert, T., & Prante, O. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.12.026 · Cited by 25

Analogs of the dopamine D4 receptor ligand FAUC 113 with planar- and central-chirality

Löber, S., Ortner, B., Bettinetti, L., Hübner, H., & Gmeiner, P. (2002) · Tetrahedron Asymmetry · doi:10.1016/s0957-4166(02)00639-0 · Cited by 25

1-Aminoindanes as novel motif with potential atypical antipsychotic properties

Graham, J. M., Coughenour, L. L., Barr, B. M., Rock, D. L., & Nikam, S. S. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.11.106 · Cited by 24

Fancy bioisosteres: Synthesis, SAR, and pharmacological investigations of novel nonaromatic dopamine D3 receptor ligands

Lenz, C., Boeckler, F. M., Hübner, H., & Gmeiner, P. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.04.047 · Cited by 24

Enantiospecific synthesis and receptor binding of novel dopamine receptor ligands employing natural 4-hydroxyproline as a practical and flexible building block

Heindl, C., Hübner, H., & Gmeiner, P. (2003) · Tetrahedron Asymmetry · doi:10.1016/j.tetasy.2003.08.020 · Cited by 24

Positron-Labeled Dopamine Agonists for Probing the High Affinity States of Dopamine Subtype 2 Receptors

Hwang, D., Narendran, R., & Laruelle, M. A. (2004) · Bioconjugate Chemistry · doi:10.1021/bc049834n · Cited by 23

Pharmacological evaluation of selected arylpiperazines with atypical antipsychotic potential

Tomić, M., Kundaković, M., Butorović, B., Janać, B., Andrić, D. B., Roglić, G., Ignjatović, Đ., & Kostić‐Rajačić, S. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.06.005 · Cited by 23

Haloperidol: towards further understanding of the structural contributions of its pharmacophoric elements at D2-like receptors

Sikazwe, D., Li, S., Mardenborough, L. G., Cody, V., Roth, B. L., & Ablordeppey, S. Y. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.09.046 · Cited by 23

8,9-Dihydroxy-1,2,3,11b-tetrahydrochromeno[4,3,2,-de]isoquinoline (dinoxyline), a high affinity and potent agonist at all dopamine receptor isoforms

Grubbs, R. A., Lewis, M. M., Vance, C. O., Gay, E. A., Jassen, A. K., Mailman, R. B., & Nichols, D. E. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.01.008 · Cited by 23

The weaver mutant mouse: a model to study the ontogeny of dopamine transmission systems and their role in drug addiction

Maharajan, P., Maharajan, V., Ravagnan, G., & Paino, G. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00061-7 · Cited by 22

D2 Receptor Partial Agonists: Treatment of CNS Disorders of Dopamine Function

Kehne, J. H., Andree, T. H., & Heinrich, J. N. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608785161394 · Cited by 20

The QT interval and the atypical antipsychotic, sertindole

Fritze, J., & Bandelow, B. (1998) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651509809115372 · Cited by 20

Phenylpiperazinylmethylindolecarboxylates and derivatives as selective D4-Ligands

Moll, A., Hübner, H., Gmeiner, P., & Troschütz, R. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(02)00042-1 · Cited by 20

In vitro and in vivo evaluation of the binding of the dopamine D2 receptor agonist11C-(R,S)-5-hydroxy-2-(di-n-propylamino)tetralin in rodents and nonhuman primate

Mukherjee, J., Narayanan, T. K., Christian, B., Shi, B., Dunigan, K. A., & Mantil, J. (2000) · Synapse · Cited by 19

Cyclic Amidines as Benzamide Bioisosteres: EPC Synthesis and SAR Studies Leading to the Selective Dopamine D4 Receptor Agonist FAUC 312

Einsiedel, J., Hübner, H., & Gmeiner, P. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00004-0 · Cited by 19

SONU20176289, a compound combining partial dopamine D2 receptor agonism with specific serotonin reuptake inhibitor activity, affects neuroplasticity in an animal model for depression

Michael-Titus, A. T., Albert, M., Michael, G. J., Michaelis, T., Watanabe, T., Frahm, J., Pudovkina, O. L., van der Hart, M. G. C., Hesselink, M. B., Fuchs, E., et al. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.09.006 · Cited by 19

Stereocontrolled dopamine receptor binding and subtype selectivity of clebopride analogues synthesized from aspartic acid

Einsiedel, J., Weber, K., Thomas, C., Lehmann, T. J., Hübner, H., & Gmeiner, P. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00678-4 · Cited by 18

Ex-chiral pool synthesis and receptor binding studies of 4-substituted prolinol derivatives

Heindl, C., Hübner, H., & Gmeiner, P. (2003) · Tetrahedron Asymmetry · doi:10.1016/j.tetasy.2003.08.019 · Cited by 17

Synthesis and binding affinity of novel 3-aminoethyl-1-tetralones, potential atypical antipsychotics

Alvarado, M., Coelho, A., Masaguer, C. F., Raviña, E., Brea, J. M., Padín, J. F., & Loza, M. I. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.04.022 · Cited by 17

The acute EPS of haloperidol may be unrelated to its metabolic transformation to BCPP+

Sikazwe, D., Li, S., Lyles-Eggleston, M., & Ablordeppey, S. Y. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.07.015 · Cited by 15

Synthesis of 6-substituted 1-phenylbenzazepines and their dopamine D1 receptor activities

Zhang, J., Chen, X., Yu, L.-P., Zhen, X., & Zhang, A. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.09.049 · Cited by 14

MDL-100907

Sorbera, L. A., Silvestre, J. S., & Castañer, J. (1998) · Drugs of the Future · doi:10.1358/dof.1998.023.09.471198 · Cited by 14

Synthesis, binding properties and receptor docking of 4-halo-6-[2-(4-arylpiperazin-1-yl)ethyl]-1H-benzimidazoles, mixed ligands of D2 and 5-HT1A receptors

Andrić, D. B., Roglić, G., Šukalović, V. V., et al. (2007) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2007.09.027 · Cited by 13

The discovery of potent and selective dopamine D4 receptor antagonists

Faraci, W. S., Zorn, S. H., Sanner, M. A., & Fliri, A. F. J. (1998) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(98)80131-2 · Cited by 13

SAR Study of 1-Aryl-4-(phenylarylmethyl)piperazines as Ligands for Both Dopamine D2 and Serotonin 5-HT1A Receptors Showing Varying Degrees of (Ant)agonism. Selection of a Potential Atypical Antipsychotic

Feenstra, R., van den Hoogenband, A., Stroomer, C. N. J., van Stuivenberg, H. H., Tulp, M. T. M., Long, S., van der Heyden, J. A. M., & Kruse, C. G. (2006) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.54.1326 · Cited by 12

Synthesis and Preliminary Pharmacological Evaluation of 4′-Arylalkyl Analogues of Clozapine. IV.* The Effects of Aromaticity and Isosteric Replacement

Capuano, B., Crosby, I. T., Lloyd, E. J., Podloucka, A., & TAYLOR, D. A. H. B. (2008) · Australian Journal of Chemistry · doi:10.1071/ch08307 · Cited by 12

Synthesis of potent and selective dopamine D4 antagonists as candidate radioligands

Huang, Y. H., Kegeles, L. S., Bae, S.-A., Hwang, D., Roth, B. L., Savage, J. E., & Laruelle, M. A. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00241-4 · Cited by 10

Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part I: Influence of the substitution on the basic nitrogen and the position of the amide on the affinity for D2L, D4.2, and 5-HT2A receptors

Carato, P., Graulich, A., Jensen, N., Roth, B. L., & Liégeois, J.-F. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.12.096 · Cited by 10

Therapeutic and Diagnostic Agents for Parkinson's Disease

Neumeyer, J. L., Baldessarini, R. J., & Booth, R. G. (2003) · Wiley eBooks · doi:10.1002/0471266949.bmc105 · Cited by 10

Dopamine/serotonin receptor ligands. Part 17: A cross-target SAR approach: Affinities of azecine-styled ligands for 5-HT2A versus D1 and D2 receptors

Enzensperger, C., Görnemann, T., Pertz, H. H., & Lehmann, J. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.04.081 · Cited by 9

Evaluation of the eutomer of 4-{3-(4-chlorophenyl)-3-hydroxypyrrolidin-1-yl}-1-(4-fluorophenyl)butan-1-one, {(+)-SYA 09}, a pyrrolidine analog of haloperidol

Ablordeppey, S. Y., Lyles-Eggleston, M., Bricker, B. A., Zhang, W., Zhu, X. Y., Goodman, C. B., & Roth, B. L. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.03.057 · Cited by 8

Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part II: Influence of the substitution on the benzyl moiety on the affinity for D2L, D4.2, and 5-HT2A receptors

Carato, P., Graulich, A., Jensen, N., Roth, B. L., & Liégeois, J.-F. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.12.106 · Cited by 8

[Dopamine control of neuroendocrine functions. New findings based on the study of transgenic animals].

Jaber, M. (1997) · PubMed · Cited by 4

Bioinspired catecholic chemistry for surface modification

Ye, Q., Zhou, F., & Liu, W. (2011) · Chemical Society Reviews · doi:10.1039/c1cs15026j · Cited by 1,177

Arylsulfonylacetamides as bifunctional reagents for alkene aminoarylation

Monos, T. M., McAtee, R. C., & Stephenson, C. R. J. (2018) · Science · doi:10.1126/science.aat2117 · Cited by 355

Activation of AMPK/mTORC1-mediated autophagy by metformin reverses Clk1 deficiency-sensitized dopaminergic neuronal death

Yan, Q., Han, C., Wang, G., Waddington, J. L., Zheng, L., & Zhen, X. (2017) · Molecular Pharmacology · doi:10.1124/mol.117.109512 · Cited by 77

D1 and D5 dopamine receptors participate on the consolidation of two different memories

Furini, C. R. G., Myskiw, J. C., Schmidt, B. E., Marcondes, L. A., & Izquierdo, I. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.06.027 · Cited by 60